Becton, Dickinson and Company (BD) has introduced advanced prefillable syringe for higher volume injection of biologics.
The BD Neopak 2.25 mL prefillable glass syringe has been designed specifically for biopharmaceutical manufacturers that develop, manufacture and market sensitive biologic drugs that need better quality levels and performance for the treatment of chronic diseases like rheumatoid arthritis, psoriasis, lupus and severe asthma.
The syringe is said to decrease undesired interactions such as drug degradation or aggregation between the primary container and drug, helping biopharmaceutical manufacturers to reduce their development and commercialization risks.
The company, which also produces Neopak 1mL glass prefillable syringe, is marketing the new Neopak 2.25mL prefillable glass syringe in the US, Europe and Japan.
BD pharmaceutical systems worldwide president Peter Nolan said: “Through our continued investment in innovation, this new syringe enables biopharmaceutical manufacturers to develop drug-syringe combination products with extended injection intervals.
“This will provide patients with more time between injections and decrease the frequency of injections.
“By offering higher volume subcutaneous injections, the BD Neopak 2.25 mL prefillable glass syringe is designed to help reduce the number of necessary injections, aiming to improve the safety and convenience for patients.”
In November, BD also launched new insulin syringe, which was developed for diabetes people taking Eli Lilly manufactured Humulin R U-500 insulin.
Humulin R U-500 is concentrated insulin developed to treat high blood sugar in people with diabetes who need to inject more than 200 units of insulin per day.
The new BD U-500 insulin syringe has been designed to draw the correct dose of U-500 insulin by reducing steps.